



Sci B Vac Proven to Prevent Recurrence of Hepatitis B

11th June 2007: Scigen Limited (ASX:SIE) announces that Sci B Vac, Scigen's third generation hepatitis B vaccine derived from mammalian cells (CHO), has been proven to prevent recurrence of hepatitis B virus infection in patients receiving antiviral prophylaxis (Lamivudine) after liver transplantation for chronic hepatitis B.

Anti-virals (Lamivudine) monophylaxis against hepatitis B virus (HBV) administered to prevent reinfection after liver transplantation is associated with recurrence due to escape mutants. Second generation recombinant HBV vaccine derived from yeast given in combination with anti-viral is not effective in preventing such recurrence.

In an investigator sponsored study at the Center for the study of Liver Disease at the University of Hong Kong and published in the American Journal of Transplantation (2007:7:434-439) a combination of antiviral Lamivudin with Sci B Vac was administered to 20 patients. The response rate was 88% in patients younger than 50 years old and 25% in older patients. At the completion of the study all patients remained free of infection.

Hepatitis B Virus (HBV) is a major world health problem. There are over 300 Million chronic carriers of infection and over 1 million deaths each year are attributed to hepatitis B. The world market for the prevention and treatment of Hepatitis B virus is believed to be over US\$3 Billion dollars and growing.

About Sci B Vac™ :

Sci B Vac™ is a third generation recombinant hepatitis B Vaccine produced by Chinese Hamster ovary cells. Sci B Vac™ contains immunogenic regions of the three surface proteins of HBV.

Sci B Vac™ is a unique hepatitis B vaccine, which has repeatedly been shown to be highly immunogenic and safe in neonates, children and adults alike.

Worldwide sales of hepatitis B vaccines are estimated to be US\$1.2 billion.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.



SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

Further information:

Company – Investor Relations	Company
Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)